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The effect of anthralin and its oxidation products, 
anthralin-dimer and anthralin-quinone, on protein con-
tent and thymidine incorporation as well as C02 produc-
tion from glucose and glutamine has been studied in 
transformed human keratinocytes in vitro. Anthralin 
exhibited the strongest inhibition, the dimer was gen-
erally less active and the quinone inactive. Respiration 
and thymidine incorporation were the most sensitive 
cellular functions showing 50% inhibition at about 1 and 
3 J.LM anthralin, respectively. Comparison of the inhibi-
tion kinetics of anthralin with those of antimycin A and 
mitomycin C showed that anthralin behaved as an inhib-
itor of mitochondrial function rather than of DNA rep-
lication. The biologic effects were triggered in the first 
minutes of exposure to the cells when anthralin became 
rapidly associated with the cell membranes. Labeling 
experiments with [14 C]anthralin revealed that the man-
ifestation of the biologic response occurring after a la-
tency phase of some hours coincided with the accumu-
lation of radioactivity in the intracellular particulate 
fraction. The cytosol remained essentially unlabeled. 
The discovery of the antipsoriatic activity of chrysarobin 
(1,8-dihydroxy-3-methyl-9-anthrone) [1] and subsequently of 
anthralin (dithranol, cignolin, 1,8-dihydroxy-9-anthrone) [2,3] 
has stimulated investigations on the molecular mode of action 
of thi s group of antiproliferative compounds. Essentially three 
different cellular targets are discussed: 
1. DNA replication and repair synthesis are inhibited [4,5]. 
A direct interaction of anthralin with cellular DNA as proposed 
by Swanbeck and Thyresson [6], however, has been questioned 
(7,8]. 
2. Mitochondrial structure and function are affected, leading 
to inhibition of cellular respiration [9- 13] . 
3. Cytosolic key enzymes are impaired, for example, glucose-
6-phosphate dehydrogenase in the hexose monophosphate 
shunt [ 14- 16] . Since all three effects can independently account 
for the inhibition of cell growth and proliferation observed after 
the application of anthralin, we wanted to know which is t he 
most sensitive. 
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Abbreviations: 
DMEM: Dulbecco's modified Eagle's medium contain in g 5.5 mM 
glucose and 4 mM glutamine 
F12: Ham's medium F12 
FCS: fetal calf serum 
HEPES: 4-(2-hydroxyethyl )-piperazine-1-ethane-2-sulfonic acid 
HPLC: high-performance liquid chromat.ography 
IC50: concentration of a given compound causing 50% inhibition 
of the biologic activity under investigation 
METAMED: "metabolism test medium" (DMEM without pyru-
vate and sodium bicarbonate but wit.h 20 mM HEPES) 
TCA: trich loroacetic ac id 
The studies were performed with the transformed human 
keratinocyte line SV -Kl4. Thymidine incorporation was taken 
as a measure of DNA synthesis [17]. Carbon dioxide release 
from glutamine was used to determine respiratory activity since 
we found this amino acid to be one of the most important 
oxidative energy sources for cultured human keratinocytes 
[18]. To evaluate the effect of anthralin on the hexose mono-
phosphate pathway we measured C02 production from glucose 
taking advantage from the finding that human epidermal cells 
in vitro generate about two-thirds of this C02 via t he shunt 
and only one-third via the Krebs cycle [19). On comparing dose 
response and in hibition kinetics of anthralin on these 3 func-
tions we found respiration to be the most sensitive target. This 
finding received further support from parallel experiments us-
ing inhibitors that are known to act se lectively on DNA (mi-
tomycin C) [20] or mitochondria (antimycin A) [21). 
MATERIALS AND METHODS 
Chemicals 
Anthralin and its oxidation products, anthralin-quinone (danthron 
1,8-dihydroxy-anthraquinone) and anthralin -dimer (1 ,8,1 ',8' -tetrahy: 
droxy-10,10'-dianthrone). were kindly provided by Dr. J. Maignan 
(L'Oreal, Aulnay-sous-Bois) and Dr. B. Shroot (CIRD, Valbonne); [10-
"C]anthralin was prepared by Dr. J.-P . Frideling (CIRD, Valbonne). 
Cation ic silica microbeads were a generous gift of Dr. B. Jacobson 
(Univers ity of Massachusetts, Amherst). Antimycin A and mitomycin 
C were from Boehringer Mannheim. Cu lture media and fetal calf serum 
(FCS) were purchased from Flow Laboratories and GJBCO. [Methyl-
3H]thymidine, [U-"C]glucose, and [U -"C]glutamine were from CEA, 
Gif-sur-Yvette. 
Stability of the Compounds 
The spontaneous oxidation of anthralin in solut ion was followed by 
high-performance liquid chromatography (HPLC). At different times 
aliquots of t he solutions were diluted and subjected to HPLC ana lysis 
using the chromatographic equipment and t he conditions described 
elsewhere [16]. 
Cells and Culture Conditions 
The SV-40 transformed human foreskin kerati nocyte line SV-K14 
(a kind gift of Dr. B. Lane, Imperial Cancer Research Fund, London) 
was used after about 20 passages. The cells were grown at 37 ' C (5% 
C02, humidified atmosphere) in Dulbecco's modified Eagle's medium 
containing 5.5 mM glucose and 4 mM glu tamine: Ham's medium Fl2 
(DMEM:F12) (1 :1) containing 100,000 U penicillin, 100 mg strepto-
mycin, and 250 11g amphotericin B per liter of the medium which was 
supplemented with 5- 10% FCS depending on the batch. 
Preparation of the Cells for the Experiments 
Forty-eight hours before application of the compounds, 40,000 cells 
were seeded together with 0.5 ml of the culture medium in each of the 
24 wells of a COSTAR Tissue Culture Cluster. 
Application of Anthralin. and Reference Compounds 
Immediately before use, 0.1- 10 mM stock solutions of anthralin and 
its analogs were prepared with glacial acetic ac id in which the com-
pounds are stable for several hours. These solutions were diluted a 
thousandfold with serum-free metabolism test medium (METAMED) 
and, after neutralization with 10 N NaOH, added in 0.5-ml quantities 
to each well. The use of serum-free medium was necessary since we 
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found that anthralin is partially bound and inactivated by se rum 
components. 
Mitomycin C was dissolved at 150 JlM in METAMED before its 
application , and 30 mM antimycin A in ethanol was diluted 1500-fold 
with METAMED. 
Assessment of the Biologic Effects 
The cells were exposed to the compounds for the time periods 
indicated. This was done at 37' C in a humidified incubator without 
C02 supply. Thereafter, either 25 Ill FCS was added per well or the 
medium was replaced by fresh METAMED containing 5% serum. 
To trace C02 evolution from glucose and glutamine, 0.1 llCi [1'Cj 
glucose or [14C]glu tamine was added to each well. The covers of the 
clusters were equipped with glass- fiber filters which were soaked with 
2 N KOH to trap the [1' C]carbon dioxide evolved. At the end of the 
experiment, the fi lters were dried and subjected to liquid scint illation 
counting using Pica-Fluor 30 (Packard Instruments) as the scint illation 
liquid. 
To measure thymidine incorporation in to the cells, 0.25 JlCi [ 3H) 
thymidine was added to each well. The incorporation was stopped by 
aspi rating the medium. The trichloroacetic acid (TCA)-soluble pool 
was extracted twice with 0.5 ml 5% (w/v) TCA. The remaining material 
was dissolved in 0.5 N NaO H. Aliquots were taken to measure the 
t ri tium content by scint illation counting. The protein content was 
assayed with the BIORAD method. 
Intracellular Distribution of 1'C-Label after Application of 
[1 '1C}Anthrahn 
Cells were cul tured to confluency in 75-cm2 Falcon tissue cu lture 
flasks before the growth medium was replaced by 10 ml serum -free 
METAMED containing 0.1 llmol [14C]anthralin (39 Ci/mol). 
P lasma membranes from the anthralin- treated cells were isolated at 
4' C by adapting the density pertubation technique with cationic si lica 
microbeads from Saccharomyces [22) and Dictyosteliu.rn [23) cells to 
cu ltured keratinocytes (a full description of t his procedure has been 
submitted for publication) . In brief, t rypsinized cells were coated with 
the microbeads (diameter about 50 nm , specific gravity> 2 g/cm'1) and 
lysed by hypoosmotic shock. The plasma membranes were separated 
from the cytosol and other cell organell es by low-speed centrifugation 
(4 ' C, 5 min, 200 g). T hey were recovered in the pellet (fraction "P1"). 
The supernatant was then subjected to high-speed centrifugation for 
30 min at 50,000 g (pellet "P2", supernatant "8"). The whole procedure 
required about 1 h. The radioactivity in the 3 fractions was determined 
by liquid scin ti llation countin g, and their protein content w<.s measured 
with the BlORAD assay. 
RESULTS 
In a first set of experiments, the cells were exposed for 3 h 
to different concentrations of anthralin and, in parallel, to its 
oxidation products, anthralin -dimer and a n t hra lin -quinon e (for 
structures see Fig 2). The treatment was terminated by replac-
ing t he drug-containing medium with METAMED supple-
mented with 5% FCS, ["H]t hymidine, and [14C]glu tamine or 
[l 'C]glucose. After 24 h incubation, protein content, t hym idine 
incorporation, and C02 production from glutamine and glucose 
were measured for each well as described in Ma.terial.s and 
Methods. They were related to the controls which were set to 
100%. 
Fig 1 shows t he co rresponding dose-response curves. An-
thralin revea led t he strongest inhibition: the dimer was gener-
a lly less active a nd the quinone inact ive. The dimer inhibited 
al l parameters at ICr,0 values of about 6 !lM. The effect of 
anthralin was more specific: in the average of 11 independen t 
experimen ts, 50% inhibition was ac hieved at about 1 llM for 
the respiration of glutamine, at 3 llM for t hymidine incorpora-
tion and CO" production from glucose, and at 10 !lM for the 
protein conten t. The IC50's obtained from different experiments 
varied between half a nd double these values. The variations 
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FIG 1. Dose- response curves for the effects of anthralin (4), an-
thralin -quinone (e) , and anthralin-djmer (+) on protein content per 
well (A), thymidine incorporation (B), glutam ine respiration (C), and 
CO, production from glucose (D) . T he cells were treat.ed for 3 h with 
the compounds in the absence of serum. T he biologic response was 
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FIG 2. Disappearance of anthralin (initial concentration 1 !JM) from 
serum -free cul ture medium (4, structure A) by chemical oxidation to 
anthralin -qu inone (e, structure 8), anthralin-dimer (0 , structure C) 
and to an undefined material ("anthralin-brown ", *) which is not 
detectable by HPLC. The amount of the latter was calculated by 
subtraction. 
incorporation and 0.67 !lM and 0.73 !lM for glutamine respira-
tion, indicating that this dose-response parameter is relatively 
insensitive to variations in the response time. In order to obtain 
more information about (i) t he time course of anthral in decom-
position in the incubation medium a nd (ii) the time courses of 
induction a nd manifestation of t he biologic effects, the follow -
ing kinetic experiments were performed. S ince t he incubation periods chosen for anthra lin exposure (3 
h) and the expression of t he biologic response (24 h ) were 
arbitrary, we compared in a first control experiment the dose-
response at 10.5 h a nd 24 h after a 3-h treatment with anthralin: 
the respective IC50 values were 5.0 11M and 6.5 11M for thymidine 
When anthra lin was transferred from glacial acetic acid (in 
which it was stable for several hours) to serum-free culture 
medium (in which it was app lied to t he cells), it disappeared 
exponentially as confirmed by HPLC analysis (Fig 2). After 1-
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2 h, a constant level of anthralin (or a comigrating decompo-
sition product) was observed. During this time 2 other deriva-
t ives, which were eluted at the positions of anthralin-dimer and 
anthralin-quinone, appeared. At equilibrium (about 3 h after 
dilution) , the detectable molecular species amounted to 48% of 
the init ial ant hralin concentration. They were recovered as 
20% "anthralin ," 16% "dimer," and 12% "quinone." The other 
52% was converted to an undetectable oxidation product, most. 
probably "anthralin brown," which was retained by the column. 
In the next experiment, t he cells were exposed to a fixed 
concentration of anthralin (3 J.LM) for different t imes. The 
expression of the biologic response was determined 24 h later. 
As shown in Fig 3, an incubation time of 15 min was sufficient 
to trigger most of the biologic effects under investigation. Only 
t he maximum inhibition of C02 production from glucose re-
quired a longer incubation. In this particular experiment, thy-
midine incorporation was the least affected parameter, followed 
by the protein content per well, and the conversion of glucose 
to C02. In agreement with the first experiment, respiration of 
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FIG 3. The time dependency of anthralin action on protein content 
per well (A), t hymidine incorporation (B), glutamine respiration (C) , 
a nd C02 production from glucose (D). The cells were treated for 
different times with 3 J.LM ant hralin in serum-free medium. The biologic 




















































FIG 4. Carbon diox ide production from glu tam ine (A) and thymi -
dine (B) incorporation in the absence (e) and in the presence of 3 J.LM 
anthralin (A), 20 J.LM antimycin A (6), and 150 J.LM mi tomycin C (0). 
The compounds were added at zero time in serum -free medium; the 
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FIG 5. In t racellula r distribut ion of the radioactivity from ["C]an-
thralin (A) and t he distribution of proteins (B) in 3 cellular subfrac-
tions. PI = plasma membrane fraction; P2 = int racellular particulate 
fraction (mainly mitochondria and lysosomes); S = 50,000 g superna -
tant (mainly cytosol). The cells were incubated either for 10 min 1 h 
or 5 h with 10 J.LM ["C]anthralin in serum-free medium (left sid,e) o; 
for 10 min with ["C]anthralin followed by an incubation in fresh 
serum-containing medium (right side). The areas of the circles are 
proport ional to the total radioactivity incorporated into the cells. The 
open sectors correspond to the radioactivity removable by serum-con-
tain ing medium. In parentheses, ["C) concentrations are given (fmol/ 
cell) . 
The following experiment was designed to estimate the time 
necessary for the manifestation of the biologic response after 
the application of 3 J.LM anthralin. We restricted ourselves to 
the study of thymidine incorporation and glutamine respira-
tion, but included 2 other compounds that are known to act 
specifically on either DNA or respiration: mitomycin C, which 
is presumed to interact with guanine residues thereby inhibiting 
DNA replication [20], and antimycin A, which interrupts the 
electron transport chain between cytochromes band c, (21] . In 
contrast to the other experiments, the cells were preincubated 
for 3 h with the radioactive glutamine before adding inhibitors 
and [3H]thymidine since we found that the evolution of (14C] 
carbon dioxide from [14C]glutamine occurred with a lag phase 
of about this duration. After 1-h exposure, 25 J.Ll FCS was added 
to each well. [14C]carbon dioxide evolution and [3H]thymidine 
incorporation were monitored over the next 9 h. 
Fig 4A shows that respiration was affected 1 h after the 
addition of 20 J.LM antimycin and 4 h after the addition of 3 J.LM 
anthralin. This inhibition was accompanied by an evident but 
less pronounced reduction in thymidine incorporation (Fig 4B). 
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Mitomycin at 150 J.LM, on the other hand, needed 1 h to reduce 
the incorporation of thymidine but 8 h to affect respiration. 
Since the experiments described above indicated that respi-
ration is the primary target of anthralin action and since the 
last 2 experiments showed clearly that there is a latency phase 
between the triggering of the biologic response and its manifes-
tation, it was tempting to correlate this phase with the lag time 
of the drug (or its reactive conversion product) to appear in the 
mitochondria. For this reason we measured the kinetics of the 
intracellular distribution of 14C-label from [10- 14C]anthralin. 
The cells were incubated for different times with 10 J.LM [ 14C] 
anthralin at 37oC in the absence of serum. Thereafter, 3 cellular 
subfractions were prepared as described in Materials and Meth-
ods. They consisted predominantly of plasma membranes (frac-
tion P1), mitochondria and lysosomes (fraction P2) [24], cyto-
sol and light particulate material (fraction S). Nuclei were 
largely destroyed during membrane preparation and were pre-
sumed to contribute mainly to fraction S. 
The results of the experiment are given in Fig 5A (left side). 
After 10 min, 1 h, and 5 h of incubation, 2.00, 2.18, and 3.13 
fmol (1''C]carbon per cell, respectively, were recovered, corre-
sponding to 7.5, 8.2, and 11.8% of the radioactivity supplied. 
After the 10-min incubation, more than 50% of the label was 
found in the plasma membranes, the rest in fraction P2. With 
increasing time, the radioactivity was successively translocated 
from fraction P1 to fraction P2 which, after 5 h, contained 
almost 90% of the label. The supernatant remained essentially 
free of radioactivity. 
In a parallel experiment, cells were treated as before for 10 
min with (1''C]anthralin. After aspirating the drug-containing 
medium, the cells were kept 1- 5 h in METAMED supplemented 
with 5% FCS before fractionation. During this time, 30-40% 
of the radioactivity incorporated within the first 10 min was 
released- mainly from the plasma membranes-into the me-
clium. The total amount of bound radioactivity decreased from 
2.00 via 1.39 to 1.16 fmol/cell (Fig 5A, right side). 
Both experiments led to a predominant accumulation of the 
cell-bound radioactivity in fraction P2. This was not correlated 
with the distribution of proteins (Fig 5B), indicating that the 
preferred association of anthralin (or its conversion products) 
with this fraction cannot be explained by an unspecific binding 
to proteins. 
DISCUSSION 
Anthralin inhibits different cellular functions at rather low 
concentrations. The following ICr.o values, for example, are 
reported in the literature: 1.1 J.LM and 2.3 J.LM for the inhibition 
of DNA replication and repair synthesis in T98G cells (5], 0.3 
J.LM and 1.5 J.LM for the inhibition of thymidine incorporation 
and respiration in cultured human dermal fibroblasts (25,26], 
and about 50 J.LM for the inhibition of purified yeast glucose-6-
phosphate dehydrogenase [15) or mouse epidermal arachidonic 
acid lipoxygenase (27) activity. 
From the above data obtained with fibroblasts, thymidine 
incorporation appears to be more sensitive to anthralin than 
to respiration. This interpretation, however, can be misleading 
when the experiments are not conducted under identical con-
ditions. In the experiments cited, for example, thymidine in-
corporation was studied in actively growing cells, whereas res-
piration was measured with confluent cultures in order to 
produce a stronger signal. To avoid this ambiguity, we applied, 
in the present paper, exactly the same conditions for the 
measurement of all parameters. Furthermore, we used human 
epidermal keratinocytes instead of other cell types because they 
represent a likely target cell of anthralin action in psoriasis. 
All our results obtained under such conditions inclicate that 
the inhibition of cell proliferation by anthralin, at least in 
keratinocytes, is the consequence of impaired mitochondrial 
function rather than of DNA damage. 
Furthermore, the present study shows that when keratino-
cytes are exposed to [14C]anthralin, a certain percentage of the 
label is immediately adsorbed on their plasma membranes, later 
becoming redistributed over the intracellular particulate frac-
tion (Fig 5). This rapid process, which occurs during the first 
10 min and can be partially reversed by the adclition of serum-
containing meclium, is followed by a further, much slower 
uptake of anthralin or one of its oxidation products. The first, 
rapid process is mainly responsible for the initiation of the 
biologic response since incubation times longer than 15 min do 
not give rise to quantitative changes of most of the parameters 
measured. This finding is in agreement with the report of 
Zetterberg [28] that, in yeast, the maximal induction of respi-
ration-deficient "petites" colonies by anthralin was reached 
within 5 min. 
Whereas the inhibition kinetics of thymidine incorporation, 
protein content, and glutamine respiration can be considered 
as monophasic, the inhibition of C02 production from glucose 
appears to be biphasic (Fig 3) . This peculiarity can easily be 
explained by the fact that part of the C02 production occurs 
via the Krebs cycle and the rest via the hexose monophosphate 
shunt (19], and by the assumption that the inhibition of these 
pathways follows a different time course. Further experiments, 
however, are necessary to clarify this point. 
In any case, we can state that the rapid association of 
anthralin with the plasma membrane triggers most of the 
biologic effects which become manifest some hours later (Fig 
4). The time lag between induction and expression of these 
effects can be explained, at least in part, by the intracellular 
redistribution of the reactive species, i.e., anthralin itself or one 
of its cellular conversion products. 
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